Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1654 companies, A–Z).
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
Netcapital received a Nasdaq letter on November 5, 2026 granting it an exception to regain compliance with the periodic filing rule, after it missed deadlines for its annual report for the fiscal year ended April 30, 2026 and its quarterly report for the quarter ended July 31, 2026. The company must file both reports by February 9, 2027, or Nasdaq will issue a delisting notice, which the company could appeal to a Nasdaq Hearings Panel. The letter has no immediate effect on trading, but the company says there can be no assurance it will meet the deadline.
Nasdaq Staff letter dated November 5, 2026 grants an exception under Listing Rule 5250(c)(1).
Delinquent Form 10-K (fiscal year ended April 30, 2026) and Form 10-Q (quarter ended July 31, 2026) must be filed on or before February 9, 2027.
If the deadline is missed, Nasdaq will provide written notice of delisting, and the company may appeal to a Nasdaq Hearings Panel.
The letter has no immediate effect on the listing or trading of the common stock.
Novocure said it received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, which treats adult patients with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA said uncertainty about the degree of clinical benefit prevented approval, and the company said it has no assurance that further discussions or submissions will lead to approval.
The FDA's Not Approvable Letter cites uncertainty around the degree of clinical benefit provided by Optune Mya.
The FDA did not raise concerns about the device's safety profile.
Novocure plans to meet with the FDA to see whether any options could support approval without additional clinical studies.
The filing gives no timeline for those discussions and no assurance of approval.
Knightscope received a Nasdaq deficiency letter on November 4, 2026, because its Class A Common Stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027 to regain compliance, and the notice has no immediate effect on its listing, which continues under the symbol KSCP.
Nasdaq deficiency letter received November 4, 2026 for closing below $1.00 minimum bid price for 30 consecutive business days
Compliance Date is May 3, 2027, a 180 calendar day compliance period
Regaining compliance requires closing at $1.00 or more for at least ten consecutive business days
If not compliant, the company may qualify for a second 180 calendar day period, possibly through a reverse stock split; otherwise delisting proceedings could begin, with a right to appeal to a Nasdaq Hearings Panel
Curis received a Nasdaq letter on November 2, 2026 stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days, and it is not eligible for a standard compliance period because of its recent reverse stock split. The company intends to request a new hearing, which would stay further delisting actions, but says there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.
Nasdaq letter dated November 2, 2026 cites bid price below $1.00 for 30 consecutive business days under Rule 5550(a)(2)
Company effected a 1-for-20 reverse stock split on July 6, 2026, which makes it ineligible for a compliance period
Following a Nasdaq Hearings Panel decision dated July 24, 2026, Curis is subject to a Discretionary Panel Monitor for one year
Company intends to request a new hearing; no assurance of success or continued Nasdaq listing
On November 5, 2026, the Public Service Commission of Wisconsin approved rate changes in rate cases filed in April 2026 by Wisconsin Electric Power Company, Wisconsin Gas LLC and Wisconsin Public Service Corporation. The presentation slides attached to the filing list an authorized return on equity of 9.50% and an equity ratio of 53.0%, and say a final written order is expected before year-end.
PSCW approved rate changes on November 5, 2026 for Wisconsin Electric, Wisconsin Gas and Wisconsin Public Service
Authorized return on equity of 9.50% and equity ratio of 53.0%
Earnings sharing: no sharing on the first 15 basis points above the allowed ROE, 50/50 on the next 25 basis points, and 100% to customers beyond 40 basis points
Nasdaq granted Fifth Era Acquisition Corp I (FERA) an extension to show its Class A Ordinary Shares have at least 400 Total Holders, the minimum for continued listing on the Nasdaq Global Market. If the company does not meet the terms, Nasdaq will issue a delisting notice, and the company may then appeal to a Listing Qualifications Panel, so the listing remains at risk.
Nasdaq notice dated September 14, 2026 cited non-compliance with Listing Rule 5450(a)(2), which requires at least 400 Total Holders
Company submitted its compliance plan to Nasdaq on October 28, 2026
Nasdaq granted an extension on November 5, 2026; documentation is due on or before March 15, 2027
Barfresh Food Group received a Nasdaq letter on November 5, 2026 saying its common stock closed below $1.00 for 30 consecutive business days. The company has until May 4, 2027 to regain compliance, and it also faces a separate market value requirement deadline of February 1, 2027. The notice does not change current trading, but a failure to cure could lead to delisting risk for shareholders.
Nasdaq notice received November 5, 2026 for failing the $1.00 minimum closing bid price for 30 consecutive business days
Compliance requires at least $1.00 closing bid for 10 consecutive business days by May 4, 2027, with a possible extension
Company must meet MVLS of $35,000,000 by February 1, 2027; a reverse split must be completed no later than ten business days before May 4, 2027
Common stock continues to trade on The Nasdaq Capital Market under the symbol BRFH
BioCardia said it finished its clinical consultation with Japan's PMDA on application materials for the CardiAMP Cell Therapy System for ischemic heart failure, a step toward submitting a marketing approval application. The company states that completing consultations does not constitute regulatory approval, and the product remains subject to PMDA review.
Consultation with Japan's PMDA on application materials completed, announced November 6, 2026
CardiAMP is intended for ischemic heart failure; CEO Peter Altman targets first patient treatments in Japan and commercial revenues in 2028
Completion does not equal regulatory approval; product remains subject to PMDA review
Essential Utilities disclosed that American Water, Essential Utilities and their affiliates filed a Stipulation of Settlement with the New Jersey Board of Public Utilities (NJBPU) on November 2, 2026, in the proceeding to approve the proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and is subject to review and approval by the NJBPU. The filing shows progress on regulatory approval, but the merger still requires the NJBPU's approval before it can proceed.
Stipulation of Settlement filed November 2, 2026, with all parties in the NJBPU proceeding
Stipulation posted to the NJBPU website as of November 5, 2026, and remains subject to NJBPU review and approval
Merger agreement with American Water was signed October 26, 2025; Essential Utilities would become a wholly owned subsidiary
3M agreed on November 3, 2026 to a settlement intended to resolve most PFAS-related personal injury claims in the AFFF multidistrict litigation. The company will contribute a nominal $7.35 billion from 2026 through 2034, with a present value of $5.8 billion, and will record that amount as a pre-tax charge in the fourth quarter of 2026. The company says the charge does not change its previously issued 2026 guidance, and payments depend on claimant participation thresholds.
Nominal commitment of $7.35 billion over 2026 to 2034; present value of $5.8 billion
Pre-tax charge of $5.8 billion in Q4 2026, treated as a special item in adjusted results; 3M says 2026 guidance is unchanged
$50 million payment due in 2026 and no payments in 2027; payments subject to claimant participation thresholds
Settlement covers about 99% of current personal injury claims, involving roughly 115,000 to 120,000 eligible plaintiffs; 3M does not admit liability
Spire Missouri filed a general rate case with the Missouri Public Service Commission on November 2, 2026, requesting a total revenue requirement increase of $228 million. The filing is based on an average fiscal 2028 future test year rate base of $5.1 billion, and the commission has 11 months to review it, with new rates expected by October 2027. For shareholders, the outcome will determine how much of the utility's infrastructure investment is recovered through customer rates.
Total requested revenue increase of $228 million, including $57 million through the Infrastructure System Replacement Surcharge and $171 million in net new revenues
Proposed rates are based on an average fiscal 2028 future test year rate base of $5.1 billion, assuming a 55.0% common equity ratio and 10.5% return on equity
Company estimates the average residential bill would rise about $10 per month (11%) in western Missouri and about $13 per month (15%) in eastern Missouri if approved as filed
Missouri Public Service Commission has 11 months to consider the filing; new rates expected to be effective by October 2027
On October 23, 2026, Verisk issued a statement after the Delaware Supreme Court affirmed the Delaware Chancery Court judgment relating to its AccuLynx (ExactLogix) acquisition. Verisk said it will proceed in accordance with the order, but the filing states the transaction remains subject to customary closing conditions and FTC review and that there is no guarantee it will be completed.
October 23, 2026: Verisk issued a press release responding to the Delaware Supreme Court order on the ExactLogix (AccuLynx) merger.
The Delaware Supreme Court order affirmed the judgment of the Delaware Chancery Court.
Verisk says the transaction remains subject to customary closing conditions and FTC review, and that there is no guarantee it will be completed.
TXNM Energy disclosed that hearing examiners at the New Mexico Public Regulation Commission published a revised procedural schedule for the merger application on October 27, 2026. Evidentiary hearings are set for January 19 to February 1, 2027. TXNM still expects the merger with Troy ParentCo to close in the first half of 2027, but says it cannot predict the outcome.
NMPRC hearing examiners set evidentiary hearings for January 19 to February 1, 2027
The merger still requires NMPRC approval and satisfaction or waiver of customary conditions
TXNM continues to anticipate the merger closing in the first half of 2027
Dollar General disclosed that the FTC and various states filed a lawsuit against it on October 26, 2026, in federal court in Tennessee, alleging violations of the FTC Act, the Gramm-Leach-Bliley Act and state consumer protection laws. The FTC had also demanded significant monetary relief, and the company says it intends to defend the case but cannot assure a successful outcome, which could have a material adverse effect on its consolidated financial statements.
FTC and states filed suit October 26, 2026, in the U.S. District Court for the Middle District of Tennessee
Plaintiffs seek injunctive relief, monetary judgment and civil penalties; the filing does not state an amount
Draft complaint and draft settlement order were received September 23, 2026, after a Civil Investigative Demand dated January 30, 2026
Company says it will vigorously defend the matter and that defense could involve significant costs
Kinetik subsidiary EagleClaw Midstream Ventures agreed on October 23, 2026 to resolve a previously disclosed dispute with Energy Transfer over when an NGL purchase agreement expires. Under the settlement, both parties confirmed the agreement's final day of term is December 31, 2026. The filing notes that a related litigation over two Energy Transfer agreements, including this one, remains pending adjudication.
Settlement agreed October 23, 2026 between EagleClaw Midstream Ventures and Energy Transfer GC NGL Product Services
ECMV NGL purchase agreement final day of term confirmed as December 31, 2026
The agreement is one of two Energy Transfer agreements subject to previously disclosed litigation, which awaits adjudication
Quest Diagnostics said on October 21, 2026 it learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and look up results. The company believes an unauthorized party accessed certain patient records, and the full scope is still under investigation. The company said the incident has not materially disrupted its business operations or its ability to serve patients.
Unauthorized access to Quanum LSM system discovered October 21, 2026
Company believes certain patient records were accessed; full scope under investigation
Federal law enforcement notified and external cybersecurity experts engaged
Company states business operations and patient service not materially disrupted
Supernus said the FDA recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for motor fluctuations in adults with advanced Parkinson's disease, with the exclusivity period starting on the February 3, 2025 approval date. The company also submitted a supplemental New Drug Application for a second supplier of ONAPGO and continues to expect potential FDA approval of that supplier by mid-year 2027. The filing gives no financial figures, but the exclusivity period is a regulatory protection for the product.
FDA recognized seven years of orphan-drug exclusive approval for ONAPGO, with the period starting February 3, 2025.
ONAPGO is described as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson's disease.
Supernus submitted an sNDA for a second supplier of ONAPGO and expects potential FDA approval by mid-year 2027.
Collegium Pharmaceutical agreed on October 15, 2026 to settle all disputes with Grünenthal GmbH, including a patent infringement lawsuit over the Nucynta ER authorized generic. As part of the settlement, the company's license agreement with Grünenthal was terminated in its entirety, and the company made a $17 million payment, after which no further royalties are due under that license.
Settlement agreement dated October 15, 2026 resolves all disputes, including the Nucynta Litigation filed in February 2026 in the District of New Jersey
Collegium paid Grünenthal $17 million; the Grünenthal License terminated effective October 15, 2026
No further royalties will be due under the Grünenthal License; Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the lawsuit
ZoomInfo signed a memorandum of understanding on October 16, 2026, setting terms for a proposed settlement of a securities class action filed on September 4, 2024. The settlement provides for a $44 million payment to the class, a portion of which is expected to be covered by remaining insurance funds, and requires approval by the Washington District Court. The settlement would not resolve related shareholder derivative lawsuits, a related opt-out action, or a separate class action filed on June 25, 2026.
$44 million payment to the putative class, with a portion expected to be covered by remaining insurance funds
Memorandum of understanding executed October 16, 2026; subject to preliminary and final approval by the Washington District Court
Settlement would not resolve shareholder derivative suits, an opt-out direct action, or the class action filed June 25, 2026
Liquidia and its subsidiary Liquidia Technologies signed a settlement agreement with United Therapeutics on October 13, 2026, resolving all pending litigation between the companies. Liquidia will keep marketing YUTREPIA for pulmonary arterial hypertension but must remove the PH-ILD indication from the label and stop promoting it for that use, and it must make payments totaling a stated net $380.7 million in 2026 and 2027.
Net payment to United Therapeutics of $175.0 million due within 30 business days, plus $145.4 million in two $72.7 million installments due January 31, 2027 and April 30, 2027
Separate settlements with Sandoz, Henderson and PBM total about $60.3 million; the PBM agreement is with a related party that is controlled by a director, and the board's disinterested members approved it
Lender consent for a letter of credit tied to the settlement raised the minimum cash covenant under the revenue interest financing agreement from $15.0 million to $45.0 million
Preliminary, unaudited third-quarter 2026 YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026
American Express and its bank subsidiary consented to orders from the Federal Reserve and the Office of the Comptroller of the Currency to resolve regulatory reviews of parts of its financial crimes compliance program. The bank unit also agreed to pay a $350 million civil money penalty, part of which was already reserved for in prior periods. The company says the penalty does not affect its 2026 guidance, and the orders impose no asset cap and are not expected to affect 2027 guidance.
Consent orders issued October 8, 2026 by the Federal Reserve and the OCC resolve previously disclosed reviews of financial crimes compliance.
American Express National Bank agreed to pay a $350 million civil money penalty to the OCC.
A portion of the penalty was reserved for in prior periods; the company says it does not affect full-year 2026 guidance.
The orders do not impose an asset cap, and remediation costs are not anticipated to affect 2027 guidance.
A Florida state court set a December 14, 2026 hearing to decide whether to approve a proposed settlement of a shareholder derivative lawsuit and related derivative actions and demands brought on NextEra Energy's behalf. The settlement includes a $15.5 million cash payment to the company and corporate governance reforms, and it resolves claims that would otherwise continue against the individual defendants. Shareholders were notified of the proposal and their right to be heard at the hearing.
Court order dated September 22, 2026 set the Settlement Hearing for December 14, 2026 at 3:00 p.m.
Settlement consideration includes a $15.5 million cash payment to NextEra Energy and governance reforms set out in Exhibit A.
The Revised Stipulation of Settlement is dated July 29, 2026 and replaces the original stipulation dated June 11, 2026.
The hearing will also consider an agreed award of attorneys' fees and expenses for shareholder counsel.
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.